Radius Health (NASDAQ:RDUS) Institutional Investors Quarterly Sentiment

Radius Health, Inc. (NASDAQ:RDUS) Logo

Sentiment for Radius Health (NASDAQ:RDUS)

Radius Health (NASDAQ:RDUS) institutional sentiment increased to 1.72 in Q2 2018. Its up 0.93, from 0.79 in 2018Q1. The ratio has increased, as 67 funds increased or started new holdings, while 39 decreased and sold stock positions in Radius Health. The funds in our partner’s database reported: 51.82 million shares, down from 54.99 million shares in 2018Q1. Also, the number of funds holding Radius Health in their top 10 holdings was flat from 3 to 3 for the same number . Sold All: 19 Reduced: 20 Increased: 44 New Position: 23.

Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States. The company has market cap of $721.35 million. The Company’s product candidates include Abaloparatide-SC, an injectable subcutaneous formulation of abaloparatide, which has completed Phase III clinical trial for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch for use as a short wear-time transdermal patch. It currently has negative earnings. The firm is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer.

The stock decreased 2.94% or $0.48 during the last trading session, reaching $15.84. About 746,215 shares traded. Radius Health, Inc. (NASDAQ:RDUS) has declined 47.36% since December 8, 2017 and is downtrending. It has underperformed by 62.98% the S&P500.

Analysts await Radius Health, Inc. (NASDAQ:RDUS) to report earnings on March, 7. They expect $-1.27 earnings per share, up 20.13 % or $0.32 from last year’s $-1.59 per share. After $-1.09 actual earnings per share reported by Radius Health, Inc. for the previous quarter, Wall Street now forecasts 16.51 % negative EPS growth.

Mpm Asset Management Llc holds 45.65% of its portfolio in Radius Health, Inc. for 4.00 million shares. Bb Biotech Ag owns 6.20 million shares or 5.28% of their US portfolio. Moreover, Senzar Asset Management Llc has 5.15% invested in the company for 60,521 shares. The New York-based Healthcor Management L.P. has invested 1.89% in the stock. Rock Springs Capital Management Lp, a Maryland-based fund reported 1.13 million shares.

Since January 1, 0001, it had 4 insider buys, and 0 sales for $7.31 million activity.

Radius Health, Inc. (NASDAQ:RDUS) Ratings Coverage

Ratings analysis reveals 100% of Radius Health’s analysts are positive. Out of 3 Wall Street analysts rating Radius Health, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $47 while the high is $60. The stock’s average target of $52 is 228.28% above today’s ($15.84) share price. RDUS was included in 5 notes of analysts from June 11, 2018. JP Morgan maintained the stock with “Overweight” rating in Friday, November 2 report. The company was maintained on Thursday, October 11 by Morgan Stanley. The firm earned “Buy” rating on Wednesday, July 25 by Bank of America. JP Morgan maintained Radius Health, Inc. (NASDAQ:RDUS) rating on Monday, July 23. JP Morgan has “Overweight” rating and $59 target. As per Monday, June 11, the company rating was maintained by JP Morgan.

More notable recent Radius Health, Inc. (NASDAQ:RDUS) news were published by: Nasdaq.com which released: “Radius (RDUS) Q2 Loss Narrower Than Expected, Tymlos Sales Up – Nasdaq” on August 07, 2018, also Globenewswire.com with their article: “Radius Health Announces Latest 2019 Medicare Part D Coverage for TYMLOS® (abaloparatide) Injection – GlobeNewswire” published on October 03, 2018, Fool.com published: “Here’s Why Radius Health Dropped as Much as 14.7% Today – The Motley Fool” on March 02, 2018. More interesting news about Radius Health, Inc. (NASDAQ:RDUS) were released by: Benzinga.com and their article: “Daily Biotech Pulse: FDA Nod For Mallinckrodt’s Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results – Benzinga” published on November 15, 2018 as well as Seekingalpha.com‘s news article titled: “Updating My Aerie Pharmaceuticals Short – Seeking Alpha” with publication date: November 26, 2018.

Radius Health, Inc. (NASDAQ:RDUS) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.